EMA Authorised: Ifirmacombi (irbesartan;hydrochlorothiazide) — Krka, d.d., Novo mesto

View source ↗

Summary

EMA authorised Ifirmacombi, a fixed-dose combination of irbesartan and hydrochlorothiazide for hypertension, with Krka as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Ifirmacombi (irbesartan/hydrochlorothiazide)

Snippet

Status: Authorised. Therapeutic area: Hypertension. MAH: Krka, d.d., Novo mesto. Decision date: 15/01/2026